Champions' large-scale 10 Model SynScreen featuring 10 syngeneic models, providing an optimal platform for testing new immuno-oncology (IO) therapeutics within a fully intact murine immune environment.
Now enrolling until January 10, 2026
Request more information on our 10 model SynScreen
Why choose the Champions 10 model SynScreen?
10 Syngeneic Models
Screen including syngeneic models with a fully functioning, intact murine immune system
Significant Cost-Saving
Cost-effective and large-scale syngeneic studies compared to the standalone studies
Multiple Endpoint Analyses
Flow cytometry, IHC, Luminex/ELISA and more options to quantify efficacy & mechanism
Champions' premier 10 Model SynScreen is an optimal platform for preclinical testing of Immuno-Oncology therapeutics. It is an advanced syngeneic screen to evaluate efficacy and study the mechanisms of novel immunotherapies in an intact murine immune system.
-
Cost-effective, large-scale syngeneic studies across 10 lines can be conducted simultaneously, with 2-3 models starting every two weeks.
-
Available models include MC38, CT26, LLC, 4T1, EMT6, B16F10, RENCA, A20, KLN205, and MyC-CaP.
-
Multiple endpoint analyses options including options as Flow Cytometry, Luminex/ELISA, IHC and more.
-
Each model offers 20 arms, with 10 animals per arm.
-
A free PBS control arm is provided (n=10 per model).
-
Enjoy 50% off a checkpoint inhibitor arm (PD1, CTLA4, or OX40).
Syngeneic Models - Treated & Untreated Tumor Growth Curves
CT26 responds to both anti-mCTLA4 and anti-mPD1 in vivo, while MC38 responds to anti-mPD1 but not anti-mCTLA4. Plots show mean±SEM.